• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Editorial commentary: Hitting a moving target: The challenge of creating consensus treatment protocols for cardiovascular care during the coronavirus pandemic.

作者信息

Yang Eunice, Marine Joseph E

机构信息

Division of Cardiology, Department of Medicine, Johns Hopkins University School of Medicine, 600 North Wolfe St., Carnegie 572, Baltimore, MD 21787, United States.

Division of Cardiology, Department of Medicine, Johns Hopkins University School of Medicine, 600 North Wolfe St., Carnegie 572, Baltimore, MD 21787, United States.

出版信息

Trends Cardiovasc Med. 2020 Aug;30(6):326-327. doi: 10.1016/j.tcm.2020.06.002. Epub 2020 Jun 17.

DOI:10.1016/j.tcm.2020.06.002
PMID:32562772
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7833807/
Abstract
摘要

相似文献

1
Editorial commentary: Hitting a moving target: The challenge of creating consensus treatment protocols for cardiovascular care during the coronavirus pandemic.社论评论：击中移动目标：在新冠疫情期间制定心血管护理共识治疗方案的挑战。
Trends Cardiovasc Med. 2020 Aug;30(6):326-327. doi: 10.1016/j.tcm.2020.06.002. Epub 2020 Jun 17.
2
How is the cardiovascular patient managed during Covid-19 pandemic? A report from the frontline.在新冠疫情期间如何管理心血管疾病患者？来自一线的报告。
Catheter Cardiovasc Interv. 2020 Nov;96(5):E565. doi: 10.1002/ccd.28966. Epub 2020 May 20.
3
SCAI initiatives during the COVID-19 pandemic.新冠疫情期间的SCAI倡议。
Catheter Cardiovasc Interv. 2020 Nov;96(5):995-996. doi: 10.1002/ccd.29058. Epub 2020 Jun 20.
4
CAPACITY-COVID: a European Registry to determine the role of cardiovascular disease in the COVID-19 pandemic.CAPACITY-COVID：一项欧洲登记研究，旨在确定心血管疾病在新冠疫情中的作用。
Eur Heart J. 2020 May 14;41(19):1795-1796. doi: 10.1093/eurheartj/ehaa280.
5
Coronavirus disease 2019 (COVID-19) and acute cardiovascular disease management: A Chinese perspective on striking the balance.2019冠状病毒病（COVID-19）与急性心血管疾病管理：中国关于实现平衡的观点。
Resuscitation. 2020 Jul;152:36-38. doi: 10.1016/j.resuscitation.2020.05.010. Epub 2020 May 19.
6
Editorial note about SARS-CoV-2 in the pandemic era.关于大流行时代严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的编者按。
Biomedica. 2020 Oct 30;40(Supl. 2):14-15.
7
[Expert consensus on principal of clinical management of patients with severe emergent cardiovascular diseases during the epidemic period of COVID-19].《新型冠状病毒肺炎疫情期间重症急性心血管疾病患者临床管理原则专家共识》
Zhonghua Xin Xue Guan Bing Za Zhi. 2020 Mar 24;48(3):189-194. doi: 10.3760/cma.j.cn112148-20200210-00066.
8
A Commentary on "Impact of the Coronavirus (COVID-19) pandemic on surgical practice - Part 1" (International Surgery 2020; 79:168-179) The Effectiveness of Telemedicine during the COVID-19 Pandemic.关于《冠状病毒（COVID-19）大流行对外科手术实践的影响——第一部分》（《国际外科学》2020年；79卷：168 - 179页）的评论：COVID-19大流行期间远程医疗的有效性
Int J Surg. 2020 Nov;83:115-116. doi: 10.1016/j.ijsu.2020.09.008. Epub 2020 Sep 11.
9
Consensus on interhospital transfers during the COVID-19 pandemic.关于COVID-19大流行期间医院间转运的共识。
Emergencias. 2020;32(4):301-302.
10
Collateral damage of a global pandemic: implications of COVID-19 for Australians with cardiovascular disease.全球大流行的附带损害：2019冠状病毒病对澳大利亚心血管疾病患者的影响
Intern Med J. 2020 Aug;50(8):1020-1021. doi: 10.1111/imj.14939.

本文引用的文献

1
Retraction-Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis.撤稿——羟氯喹或氯喹联合或不联合大环内酯类药物治疗新型冠状病毒肺炎：一项多国注册研究分析
Lancet. 2020 Jun 13;395(10240):1820. doi: 10.1016/S0140-6736(20)31324-6. Epub 2020 Jun 5.
2
Management of Cardiovascular Disease During Coronavirus Disease (COVID-19) Pandemic.心血管疾病在冠状病毒病（COVID-19）大流行期间的管理。
Trends Cardiovasc Med. 2020 Aug;30(6):315-325. doi: 10.1016/j.tcm.2020.05.004. Epub 2020 May 28.
3
RETRACTED: Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis.撤回：羟氯喹或氯喹联合或不联合大环内酯类药物治疗新型冠状病毒肺炎：一项多国注册分析
Lancet. 2020 May 22. doi: 10.1016/S0140-6736(20)31180-6.
4
Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial.羟氯喹治疗主要为轻症和中症的 2019 冠状病毒病患者：开放标签、随机对照试验。
BMJ. 2020 May 14;369:m1849. doi: 10.1136/bmj.m1849.
5
Takotsubo Syndrome in the Setting of COVID-19.新冠肺炎背景下的应激性心肌病
JACC Case Rep. 2020 Jul 15;2(9):1321-1325. doi: 10.1016/j.jaccas.2020.04.023. Epub 2020 May 1.
6
ISTH interim guidance on recognition and management of coagulopathy in COVID-19.国际血栓与止血学会（ISTH）关于新冠病毒病（COVID-19）凝血病识别与管理的临时指南。
J Thromb Haemost. 2020 May;18(5):1023-1026. doi: 10.1111/jth.14810. Epub 2020 Apr 27.
7
Cardiac Involvement in a Patient With Coronavirus Disease 2019 (COVID-19).新冠肺炎（COVID-19）患者的心脏受累。
JAMA Cardiol. 2020 Jul 1;5(7):819-824. doi: 10.1001/jamacardio.2020.1096.
8
Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19).COVID-19 患者的致命结局对心血管的影响。
JAMA Cardiol. 2020 Jul 1;5(7):811-818. doi: 10.1001/jamacardio.2020.1017.
9
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.羟氯喹和阿奇霉素治疗 COVID-19：一项开放标签非随机临床试验的结果。
Int J Antimicrob Agents. 2020 Jul;56(1):105949. doi: 10.1016/j.ijantimicag.2020.105949. Epub 2020 Mar 20.
10
Characteristics and Outcomes of 21 Critically Ill Patients With COVID-19 in Washington State.华盛顿州 21 例 COVID-19 危重症患者的特征和结局。
JAMA. 2020 Apr 28;323(16):1612-1614. doi: 10.1001/jama.2020.4326.